Clinical investigation of medicinal products for the treatment of Duchenne and Becker muscular dystrophy

  • Email
  • Help
Current effective version

Adopted guideline

Reference numberEMA/CHMP/236981/2011, Corr. 11
Effective from01/07/2016
KeywordsDuchenne and Becker muscular dystrophy, paediatric population, genetic neuromuscular disorder, molecular diagnosis, motor function, muscle strength
DescriptionThis document provides guidance on the development of any medicinal product for the treatment of Duchenne or Becker muscular dystrophy. It addresses the identification of the target population, study design and choice of efficacy endpoints and safety parameters.

Document history 

First version

Current version

Adopted guideline

Overview of comments

Draft guideline

Concept paper

In operation: 01/07/2016–present

Published: 11/03/2016

Published: 01/03/2013

Published: 08/07/2011

Related content

How helpful is this page?

Average rating:

 Based on 20 ratings

Add your rating:

See all ratings
4 ratings
4 ratings
4 ratings
4 ratings
4 ratings

Tell us more